Hassan Vahidnezhad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hassan Vahidnezhad has a total of 684 co-authors. Here are the top co-authors by number of shared publications:
- Jouni Uitto
Department of Dermatology and Cutaneous Biology Thomas Jefferson University Philadelphia Pennsylvania USA
66 shared publications - Leila Youssefian
Department of Dermatology and Cutaneous Biology, Sidney Kimmel Medical College Thomas Jefferson University Philadelphia Pennsylvania USA
54 shared publications - Amir Hossein Saeidian
Center for Applied Genomics, The Children's Hospital of Philadelphia, Abramson Research Building, Suite 1016I, 3615 Civic Center Boulevard, Philadelphia, PA, 19104-4318, USA
42 shared publications Leila Youssefian
Center for Applied Genomics, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
30 shared publicationsSirous Zeinali
Kawsar Human Genetics Research Center, Tehran, Iran
18 shared publicationsSoheila Sotoudeh
Children's Medical Center, Center of Excellence, Tehran University of Medical Sciences, Tehran, Iran
16 shared publications
Latest Publications
- Open Access
- 18 November 2026
- Published by Elsevier in Genetics in Medicine
RDX-Associated Hearing Loss: Expanded Variant Spectrum, Founder Effect, and Mechanistic Insights from Functional Assays
- 18 November 2026
- Published by Elsevier in Genetics in Medicine
Open AccessRDX-Associated Hearing Loss: Expanded Variant Spectrum, Founder Effect, and Mechanistic Insights from Functional Assays
- Open Access
- 26 October 2026
- Published by Wolters Kluwer Health in Research in Pharmaceutical Sciences
- Vol. 21 (6) , 716-729
Comparative efficacy and safety of systemic treatments for cutaneous leishmaniasis: a systematic review and network meta-analysis
Background and purpose: Cutaneous leishmaniasis (CL) is a globally prevalent parasitic disease with various clinical manifestations and therapeutic responses. Despite available systemic therapies, comparative evidence on efficacy and safety remains limited. This systematic review and network meta-analysis (NMA) evaluated systemic therapies for CL. Experimental approach: We identified randomized controlled trials (RCTs) assessing systemic therapies through comprehensive searches of MEDLINE, Scopus, Web of Science, Embase, and Google Scholar. Monotherapy and combination regimens were evaluated for efficacy and adverse events. Study quality was assessed using the Cochrane risk of bias tool (RoB2). Heterogeneity was analyzed using Cochran’s Q test and the I 2 statistic (I 2 = 68.8%). Pairwise relative risks (RR) with 95% confidence intervals (CI) were estimated for each treatment versus placebo/control. Findings/Results: From 1569 records, 45 RCTs comprising 3331 participants were included in NMA. Meglumine antimoniate combined with allopurinol (RR = 5.61, 95% CI: [3.00-10.46]) and tamoxifen (RR = 5.50, 95% CI: [2.41-12.56]) ranked among the most effective. Subgroup analysis showed allopurinol was more effective in New World CL (NWCL, RR=5.09, 95% CI: [2.03-12.74]) than in Old World CL (OWCL). Meglumine antimoniate combinations showed enhanced efficacy, particularly with allopurinol or tamoxifen in NWCL and allopurinol or pentoxifylline in OWCL. Safety analysis was qualitative due to heterogeneity in adverse event reporting across trials. Conclusion and implications: Systemic combination therapies, especially those including meglumine antimoniate, and monotherapies like allopurinol and miltefosine, were highly effective for CL. Further high-quality RCTs with standardized outcome assessments are needed to establish species-adapted, evidence-based clinical guidelines.
- 26 October 2026
- Published by Wolters Kluwer Health in Research in Pharmaceutical Sciences
- Vol. 21 (6) , 716-729
Open AccessComparative efficacy and safety of systemic treatments for cutaneous leishmaniasis: a systematic review and network meta-analysis
Background and purpose: Cutaneous leishmaniasis (CL) is a globally prevalent parasitic disease with various clinical manifestations and therapeutic responses. Despite available systemic therapies, comparative evidence on efficacy and safety remains limited. This systematic review and network meta-analysis (NMA) evaluated systemic therapies for CL. Experimental approach: We identified randomized controlled trials (RCTs) assessing systemic therapies through comprehensive searches of MEDLINE, Scopus, Web of Science, Embase, and Google Scholar. Monotherapy and combination regimens were evaluated for efficacy and adverse events. Study quality was assessed using the Cochrane risk of bias tool (RoB2). Heterogeneity was analyzed using Cochran’s Q test and the I 2 statistic (I 2 = 68.8%). Pairwise relative risks (RR) with 95% confidence intervals (CI) were estimated for each treatment versus placebo/control. Findings/Results: From 1569 records, 45 RCTs comprising 3331 participants were included in NMA. Meglumine antimoniate combined with allopurinol (RR = 5.61, 95% CI: [3.00-10.46]) and tamoxifen (RR = 5.50, 95% CI: [2.41-12.56]) ranked among the most effective. Subgroup analysis showed allopurinol was more effective in New World CL (NWCL, RR=5.09, 95% CI: [2.03-12.74]) than in Old World CL (OWCL). Meglumine antimoniate combinations showed enhanced efficacy, particularly with allopurinol or tamoxifen in NWCL and allopurinol or pentoxifylline in OWCL. Safety analysis was qualitative due to heterogeneity in adverse event reporting across trials. Conclusion and implications: Systemic combination therapies, especially those including meglumine antimoniate, and monotherapies like allopurinol and miltefosine, were highly effective for CL. Further high-quality RCTs with standardized outcome assessments are needed to establish species-adapted, evidence-based clinical guidelines.
- 2 August 2026
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 27 (5) , 1107-1122
Systemic Comorbidities of Keloid and Hypertrophic Scars: A Phenome-Wide Association Study in a Multiethnic U.S. Pediatric Cohort
- 2 August 2026
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 27 (5) , 1107-1122
Systemic Comorbidities of Keloid and Hypertrophic Scars: A Phenome-Wide Association Study in a Multiethnic U.S. Pediatric Cohort
- 30 June 2026
- Published by BMJ in Journal of Medical Genetics
- Vol. 63 (10) , 630-639
Longest surviving patient with a homozygous splice-altering EGFR pathogenic variant presenting with skin autoinflammation and a Bartter-like salt-losing tubulopathy
Background: Bartter syndrome (BS) is a salt-losing renal tubulopathy classically characterised by hypokalaemic metabolic alkalosis and hyperreninaemic hyperaldosteronism. Methods: We investigated the genetic cause of a Bartter-like phenotype in an adolescent patient with progressive nephrocalcinosis, hypercalciuria, polyuria, metabolic alkalosis, hypokalaemia, significantly elevated urine chloride, failure to thrive, and a salt-losing tubulopathy. Additionally, the patient presented with hypergammaglobulinaemia, abnormal cerebral white matter signal changes, skin autoinflammation, and mild intellectual disability. Results: No pathogenic variants were detected in known BS-related genes, and all recessive BS genes were outside regions of homozygosity (ROH) in this patient from a consanguineous family. Instead, exome sequencing and homozygosity mapping identified a homozygous splicing variant, c.2702-2A>G, in the epidermal growth factor receptor ( EGFR ) gene within an ~28 Mb ROH on chromosome 7p. RNA-Seq and RT-PCR analysis of the patient’s RNA confirmed the pathogenicity of this variant, demonstrating aberrant splicing resulting in an in-frame retention of 27 nucleotides from intron 22 of EGFR . Immunofluorescence analysis of the proband’s skin revealed a reduced EGFR protein level, rather than a complete absence, supporting a hypomorphic effect and likely explaining compatibility with survival into adolescence. Whereas previously reported EGFR variants have been associated with severe neonatal epithelial inflammation, bowel disease, and early mortality, our findings demonstrate that a hypomorphic variant can be compatible with survival into the second decade of life. Conclusion: These findings support an association between a syndromic Bartter-like salt-losing tubulopathy with epithelial autoinflammation and a homozygous splice-altering EGFR pathogenic variant, thereby expanding the phenotypic spectrum of EGFR -associated disorders.
- 30 June 2026
- Published by BMJ in Journal of Medical Genetics
- Vol. 63 (10) , 630-639
Longest surviving patient with a homozygous splice-altering EGFR pathogenic variant presenting with skin autoinflammation and a Bartter-like salt-losing tubulopathy
Background: Bartter syndrome (BS) is a salt-losing renal tubulopathy classically characterised by hypokalaemic metabolic alkalosis and hyperreninaemic hyperaldosteronism. Methods: We investigated the genetic cause of a Bartter-like phenotype in an adolescent patient with progressive nephrocalcinosis, hypercalciuria, polyuria, metabolic alkalosis, hypokalaemia, significantly elevated urine chloride, failure to thrive, and a salt-losing tubulopathy. Additionally, the patient presented with hypergammaglobulinaemia, abnormal cerebral white matter signal changes, skin autoinflammation, and mild intellectual disability. Results: No pathogenic variants were detected in known BS-related genes, and all recessive BS genes were outside regions of homozygosity (ROH) in this patient from a consanguineous family. Instead, exome sequencing and homozygosity mapping identified a homozygous splicing variant, c.2702-2A>G, in the epidermal growth factor receptor ( EGFR ) gene within an ~28 Mb ROH on chromosome 7p. RNA-Seq and RT-PCR analysis of the patient’s RNA confirmed the pathogenicity of this variant, demonstrating aberrant splicing resulting in an in-frame retention of 27 nucleotides from intron 22 of EGFR . Immunofluorescence analysis of the proband’s skin revealed a reduced EGFR protein level, rather than a complete absence, supporting a hypomorphic effect and likely explaining compatibility with survival into adolescence. Whereas previously reported EGFR variants have been associated with severe neonatal epithelial inflammation, bowel disease, and early mortality, our findings demonstrate that a hypomorphic variant can be compatible with survival into the second decade of life. Conclusion: These findings support an association between a syndromic Bartter-like salt-losing tubulopathy with epithelial autoinflammation and a homozygous splice-altering EGFR pathogenic variant, thereby expanding the phenotypic spectrum of EGFR -associated disorders.
- Open Access
- 24 June 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (7) , 1438
Unsupervised Deep Representation Learning and Probabilistic Clustering for the Systems-Level Discovery of Germline Mutation Signatures in Pediatric Cancers
Background/Aims: While pathogenic germline variants play a critical role in pediatric cancer susceptibility, traditional clinical genetics primarily focuses on single-gene interpretations. Transitioning to a systems-level analysis of inherited variation can uncover shared biological vulnerabilities, informing genetic counseling, surveillance, and targeted therapeutics. This study aims to implement an unsupervised machine learning framework to identify and characterize Germline Mutation Signatures (GMS) across diverse pediatric malignancies, elucidating latent genomic patterns that reveal shared oncogenic mechanisms. Methods: We analyzed germline whole-exome and whole-genome sequencing (WES/WGS) data from a retrospective cohort of 420 pediatric cancer patients and matched non-cancer controls. Variants were deeply annotated to capture multi-dimensional features, including predicted pathogenicity, splice-site disruption, regulatory impact, population frequency, and sequence context. To enable robust modeling, we integrated an augmented feature set encompassing evolutionary constraint, loss-of-function intolerance, and compositionally normalized substitution spectra. These high-dimensional annotations were processed using a deep autoencoder for non-linear representation learning, followed by Gaussian Mixture Modeling (GMM) of the latent space. Results: The framework delineated 13 signatures (GMS1–GMS13), yielding an optimal Davies–Bouldin index of 1.051. These signatures map to fundamental biological processes, including DNA repair deficiencies, transcription-coupled damage, replication stress, and aberrant RNA regulation. Crucially, these GMSs transcend traditional tissue-of-origin classifications, manifesting across multiple distinct cancer types. This observation indicates convergent germline etiologies and suggests potential shared susceptibilities to pathway-directed therapies. Conclusions: The discovery of these cross-cancer signatures provides a scalable, biologically interpretable framework for decoding inherited pediatric cancer risk. While the therapeutic mapping networks identified are currently exploratory and serve as a hypothesis-generating foundation, this deep learning-driven paradigm establishes a robust basis for stratified precision medicine. Pending prospective clinical validation, this approach holds significant translational potential to move beyond single-gene paradigms toward unified, systems-level precision oncology strategies.
- 24 June 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (7) , 1438
Open AccessUnsupervised Deep Representation Learning and Probabilistic Clustering for the Systems-Level Discovery of Germline Mutation Signatures in Pediatric Cancers
Background/Aims: While pathogenic germline variants play a critical role in pediatric cancer susceptibility, traditional clinical genetics primarily focuses on single-gene interpretations. Transitioning to a systems-level analysis of inherited variation can uncover shared biological vulnerabilities, informing genetic counseling, surveillance, and targeted therapeutics. This study aims to implement an unsupervised machine learning framework to identify and characterize Germline Mutation Signatures (GMS) across diverse pediatric malignancies, elucidating latent genomic patterns that reveal shared oncogenic mechanisms. Methods: We analyzed germline whole-exome and whole-genome sequencing (WES/WGS) data from a retrospective cohort of 420 pediatric cancer patients and matched non-cancer controls. Variants were deeply annotated to capture multi-dimensional features, including predicted pathogenicity, splice-site disruption, regulatory impact, population frequency, and sequence context. To enable robust modeling, we integrated an augmented feature set encompassing evolutionary constraint, loss-of-function intolerance, and compositionally normalized substitution spectra. These high-dimensional annotations were processed using a deep autoencoder for non-linear representation learning, followed by Gaussian Mixture Modeling (GMM) of the latent space. Results: The framework delineated 13 signatures (GMS1–GMS13), yielding an optimal Davies–Bouldin index of 1.051. These signatures map to fundamental biological processes, including DNA repair deficiencies, transcription-coupled damage, replication stress, and aberrant RNA regulation. Crucially, these GMSs transcend traditional tissue-of-origin classifications, manifesting across multiple distinct cancer types. This observation indicates convergent germline etiologies and suggests potential shared susceptibilities to pathway-directed therapies. Conclusions: The discovery of these cross-cancer signatures provides a scalable, biologically interpretable framework for decoding inherited pediatric cancer risk. While the therapeutic mapping networks identified are currently exploratory and serve as a hypothesis-generating foundation, this deep learning-driven paradigm establishes a robust basis for stratified precision medicine. Pending prospective clinical validation, this approach holds significant translational potential to move beyond single-gene paradigms toward unified, systems-level precision oncology strategies.
- 26 February 2026
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (6) , 1135-1137
Navigating the Diagnosis of Epidermodysplasia Verruciformis in the Genomic Era
- 26 February 2026
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (6) , 1135-1137
Navigating the Diagnosis of Epidermodysplasia Verruciformis in the Genomic Era
- Open Access
- 13 February 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 11 (116) , eadz8360
Human LFA-1 governs T cell immune surveillance of the skin
The human integrin lymphocyte function–associated antigen 1 (LFA-1; αLβ2) is broadly expressed on leukocytes and involved in various intercellular adhesions. We report complete LFA-1 deficiency because of inherited αL (CD11a) deficiency in otherwise healthy adults of various ancestries with skin lesions due to commensal papillomaviruses. The patients had no history of invasive infections characteristic of children with inherited deficiency of β2 (CD18), which forms heterodimers with αL, αM (CD11b), αX (CD11c), or αD (CD11d). The development and function of leukocyte subsets are largely preserved in the absence of LFA-1. However, the transendothelial migration of skin-tropic cutaneous lymphocyte antigen (CLA) + memory T cells is severely impaired, resulting in their selective sequestration in the blood. Conversely, alternative integrins mediate the extravasation of other leukocytes, including other T cell subsets, to other tissues. Human LFA-1 is required for steady-state T cell homing to the skin and control of papillomaviruses but is otherwise largely redundant. Integrin-mediated T cell compartmentalization is thus essential for organ-selective immune surveillance.
- 13 February 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 11 (116) , eadz8360
Open AccessHuman LFA-1 governs T cell immune surveillance of the skin
The human integrin lymphocyte function–associated antigen 1 (LFA-1; αLβ2) is broadly expressed on leukocytes and involved in various intercellular adhesions. We report complete LFA-1 deficiency because of inherited αL (CD11a) deficiency in otherwise healthy adults of various ancestries with skin lesions due to commensal papillomaviruses. The patients had no history of invasive infections characteristic of children with inherited deficiency of β2 (CD18), which forms heterodimers with αL, αM (CD11b), αX (CD11c), or αD (CD11d). The development and function of leukocyte subsets are largely preserved in the absence of LFA-1. However, the transendothelial migration of skin-tropic cutaneous lymphocyte antigen (CLA) + memory T cells is severely impaired, resulting in their selective sequestration in the blood. Conversely, alternative integrins mediate the extravasation of other leukocytes, including other T cell subsets, to other tissues. Human LFA-1 is required for steady-state T cell homing to the skin and control of papillomaviruses but is otherwise largely redundant. Integrin-mediated T cell compartmentalization is thus essential for organ-selective immune surveillance.
- 29 January 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (9)
Genotype–phenotype correlations and cancer risk in monogenic epidermodysplasia verruciformis
- 29 January 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (9)
Genotype–phenotype correlations and cancer risk in monogenic epidermodysplasia verruciformis
- Open Access
- 1 January 2026
- Published by Wiley in Human Mutation
- Vol. 2026 (1)
Zygosity‐Dependent Phenotypic Spectrum of RELN ‐Related Disorders: 10 New Patients and Genotype–Phenotype Correlations Across 48 Kindreds
Variants in RELN lead to a range of neurodevelopmental phenotypes, from autosomal recessive lissencephaly with cerebellar hypoplasia (LCH) (LIS2) to autosomal dominant focal epilepsies. We carried out exome sequencing (ES) on 10 affected individuals from eight unrelated Iranian families with consanguinity. Nine distinct variants were identified: Four are novel; four had been deposited in ClinVar without a reported affected individual; and the ninth, c.2015C>T, p.(Pro672Leu), had been reported only in heterozygous carriers with dominant epilepsy. In this study, we report the variant for the first time in the homozygous state, in a patient with the full recessive phenotype. The patients were pooled in a systematic review following PRISMA, updated to July 2026, with 28 papers, and all variants were reannotated against NM_005045.4, under a single ACMG/AMP framework. The primary cohort comprised 80 individuals from 48 kindreds (70 previously reported, 10 new) with 48 distinctive variants, of which 41 (85%) were pathogenic or likely pathogenic and five were variants of uncertain significance; two balanced rearrangements were not in either the sequence‐variant or copy‐number frameworks; and 16 individuals from nine kindreds with monoallelic candidate or susceptibility variants were analyzed separately. The age of onset was not continuous with no reports of onsets between 2.4 and 8 years. Zygosity did not account for this separation because monoallelic individuals occurred in both onset groups; in contrast, malformations of cortical development were documented in all 32 early‐onset individuals and in none of the 23 later onset individuals with evaluable neuroimaging. ES was the diagnostic method in 65% of individuals. Thus, zygosity contributes to the phenotypic severity in a broad spectrum of RELNopathies and supports carrier testing and reproductive counseling in consanguineous families.
- 1 January 2026
- Published by Wiley in Human Mutation
- Vol. 2026 (1)
Open AccessZygosity‐Dependent Phenotypic Spectrum of RELN ‐Related Disorders: 10 New Patients and Genotype–Phenotype Correlations Across 48 Kindreds
Variants in RELN lead to a range of neurodevelopmental phenotypes, from autosomal recessive lissencephaly with cerebellar hypoplasia (LCH) (LIS2) to autosomal dominant focal epilepsies. We carried out exome sequencing (ES) on 10 affected individuals from eight unrelated Iranian families with consanguinity. Nine distinct variants were identified: Four are novel; four had been deposited in ClinVar without a reported affected individual; and the ninth, c.2015C>T, p.(Pro672Leu), had been reported only in heterozygous carriers with dominant epilepsy. In this study, we report the variant for the first time in the homozygous state, in a patient with the full recessive phenotype. The patients were pooled in a systematic review following PRISMA, updated to July 2026, with 28 papers, and all variants were reannotated against NM_005045.4, under a single ACMG/AMP framework. The primary cohort comprised 80 individuals from 48 kindreds (70 previously reported, 10 new) with 48 distinctive variants, of which 41 (85%) were pathogenic or likely pathogenic and five were variants of uncertain significance; two balanced rearrangements were not in either the sequence‐variant or copy‐number frameworks; and 16 individuals from nine kindreds with monoallelic candidate or susceptibility variants were analyzed separately. The age of onset was not continuous with no reports of onsets between 2.4 and 8 years. Zygosity did not account for this separation because monoallelic individuals occurred in both onset groups; in contrast, malformations of cortical development were documented in all 32 early‐onset individuals and in none of the 23 later onset individuals with evaluable neuroimaging. ES was the diagnostic method in 65% of individuals. Thus, zygosity contributes to the phenotypic severity in a broad spectrum of RELNopathies and supports carrier testing and reproductive counseling in consanguineous families.
- Open Access
- 28 October 2025
- Published by Elsevier in JAAD Case Reports
- Vol. 67, 81-84
Successful treatment of an MBTPS2-linked Olmsted syndrome patient using erlotinib
- 28 October 2025
- Published by Elsevier in JAAD Case Reports
- Vol. 67, 81-84
Open AccessSuccessful treatment of an MBTPS2-linked Olmsted syndrome patient using erlotinib